Creditors and court approve Danish pharma restructuring
Copenhagen-based biopharmaceutical company Orphazyme has secured creditor and court approval of its restructuring proposal in Denmark, paving the way for it to sell its assets to US pharma group KemPharm.
To read more
Subscribe to Global Restructuring Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Restructuring Review experts.